Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions

R. Cauda, D. Goletti, M. B. Lucia, M. Tumbarello, C. Rumi, A. M. Orengo, A. Moretta

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In this study we analyzed the expression of EB6 and GL183, which are part of P58 molecular family that represents the putative NK receptor for MHC class I molecules, in peripheral blood lymphocytes of 60 patients with HIV infection (20 asymptomatic HIV-seropositive individuals, 20 patients with constitutional symptoms, and 20 AIDS patients) and correlated it with the level of CD4+, CD56+ cells, and the NK cell activity in order to determine a possible relation with disease progression. The absolute number (but not the percentage) of CD56+, EB6+, and GL183+ cells was significantly reduced only in AIDS patients but not in the other AIDS-related clinical conditions. On the contrary, NK cell activity was reduced in all HIV-infected patients. In a 6-month follow-up, patients with constant clinical conditions and stable CD4+ cells level showed no significant difference, either in the percentage or absolute number of EB6+ and GL183+ cells. Interestingly, dual-color fluorescence indicates that GL183 and EB6 molecules (that in normal individuals are virtually absent on CD3- NK cells) are expressed in HIV-infected individuals not only in CD56+ cells but also in CD3+ cells. This may reflect a depletion of other T cell subsets or alternatively (less likely) a specific immune response. Our data indicate that the expression of EB6 and GL183 in T and NK cells from HIV-infected patients might be relevant in the course of the disease and for the disease-associated functional defect of NK cell activity.

Original languageEnglish
Pages (from-to)198-205
Number of pages8
JournalClinical Immunology and Immunopathology
Volume70
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Surface Antigens
Natural Killer Cells
Acquired Immunodeficiency Syndrome
HIV
Natural Killer T-Cells
T-Lymphocyte Subsets
HIV Infections
Disease Progression
Color
Fluorescence
Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions. / Cauda, R.; Goletti, D.; Lucia, M. B.; Tumbarello, M.; Rumi, C.; Orengo, A. M.; Moretta, A.

In: Clinical Immunology and Immunopathology, Vol. 70, No. 3, 1994, p. 198-205.

Research output: Contribution to journalArticle

@article{8b371f59561140e78b55e41aaac30787,
title = "Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions",
abstract = "In this study we analyzed the expression of EB6 and GL183, which are part of P58 molecular family that represents the putative NK receptor for MHC class I molecules, in peripheral blood lymphocytes of 60 patients with HIV infection (20 asymptomatic HIV-seropositive individuals, 20 patients with constitutional symptoms, and 20 AIDS patients) and correlated it with the level of CD4+, CD56+ cells, and the NK cell activity in order to determine a possible relation with disease progression. The absolute number (but not the percentage) of CD56+, EB6+, and GL183+ cells was significantly reduced only in AIDS patients but not in the other AIDS-related clinical conditions. On the contrary, NK cell activity was reduced in all HIV-infected patients. In a 6-month follow-up, patients with constant clinical conditions and stable CD4+ cells level showed no significant difference, either in the percentage or absolute number of EB6+ and GL183+ cells. Interestingly, dual-color fluorescence indicates that GL183 and EB6 molecules (that in normal individuals are virtually absent on CD3- NK cells) are expressed in HIV-infected individuals not only in CD56+ cells but also in CD3+ cells. This may reflect a depletion of other T cell subsets or alternatively (less likely) a specific immune response. Our data indicate that the expression of EB6 and GL183 in T and NK cells from HIV-infected patients might be relevant in the course of the disease and for the disease-associated functional defect of NK cell activity.",
author = "R. Cauda and D. Goletti and Lucia, {M. B.} and M. Tumbarello and C. Rumi and Orengo, {A. M.} and A. Moretta",
year = "1994",
doi = "10.1006/clin.1994.1029",
language = "English",
volume = "70",
pages = "198--205",
journal = "Clinical Immunology and Immunopathology",
issn = "0090-1229",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions

AU - Cauda, R.

AU - Goletti, D.

AU - Lucia, M. B.

AU - Tumbarello, M.

AU - Rumi, C.

AU - Orengo, A. M.

AU - Moretta, A.

PY - 1994

Y1 - 1994

N2 - In this study we analyzed the expression of EB6 and GL183, which are part of P58 molecular family that represents the putative NK receptor for MHC class I molecules, in peripheral blood lymphocytes of 60 patients with HIV infection (20 asymptomatic HIV-seropositive individuals, 20 patients with constitutional symptoms, and 20 AIDS patients) and correlated it with the level of CD4+, CD56+ cells, and the NK cell activity in order to determine a possible relation with disease progression. The absolute number (but not the percentage) of CD56+, EB6+, and GL183+ cells was significantly reduced only in AIDS patients but not in the other AIDS-related clinical conditions. On the contrary, NK cell activity was reduced in all HIV-infected patients. In a 6-month follow-up, patients with constant clinical conditions and stable CD4+ cells level showed no significant difference, either in the percentage or absolute number of EB6+ and GL183+ cells. Interestingly, dual-color fluorescence indicates that GL183 and EB6 molecules (that in normal individuals are virtually absent on CD3- NK cells) are expressed in HIV-infected individuals not only in CD56+ cells but also in CD3+ cells. This may reflect a depletion of other T cell subsets or alternatively (less likely) a specific immune response. Our data indicate that the expression of EB6 and GL183 in T and NK cells from HIV-infected patients might be relevant in the course of the disease and for the disease-associated functional defect of NK cell activity.

AB - In this study we analyzed the expression of EB6 and GL183, which are part of P58 molecular family that represents the putative NK receptor for MHC class I molecules, in peripheral blood lymphocytes of 60 patients with HIV infection (20 asymptomatic HIV-seropositive individuals, 20 patients with constitutional symptoms, and 20 AIDS patients) and correlated it with the level of CD4+, CD56+ cells, and the NK cell activity in order to determine a possible relation with disease progression. The absolute number (but not the percentage) of CD56+, EB6+, and GL183+ cells was significantly reduced only in AIDS patients but not in the other AIDS-related clinical conditions. On the contrary, NK cell activity was reduced in all HIV-infected patients. In a 6-month follow-up, patients with constant clinical conditions and stable CD4+ cells level showed no significant difference, either in the percentage or absolute number of EB6+ and GL183+ cells. Interestingly, dual-color fluorescence indicates that GL183 and EB6 molecules (that in normal individuals are virtually absent on CD3- NK cells) are expressed in HIV-infected individuals not only in CD56+ cells but also in CD3+ cells. This may reflect a depletion of other T cell subsets or alternatively (less likely) a specific immune response. Our data indicate that the expression of EB6 and GL183 in T and NK cells from HIV-infected patients might be relevant in the course of the disease and for the disease-associated functional defect of NK cell activity.

UR - http://www.scopus.com/inward/record.url?scp=0028351235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028351235&partnerID=8YFLogxK

U2 - 10.1006/clin.1994.1029

DO - 10.1006/clin.1994.1029

M3 - Article

VL - 70

SP - 198

EP - 205

JO - Clinical Immunology and Immunopathology

JF - Clinical Immunology and Immunopathology

SN - 0090-1229

IS - 3

ER -